Moneycontrol
Get App
SENSEX NIFTY
you are here:

Kilitch Drugs (India) Ltd.

BSE: 524500 | NSE: KILITCH |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE729D01010 | SECTOR: Pharmaceuticals

Success
Alert
Please select a Day.
Info

BSE Live

Feb 24, 16:00
113.25 2.20 (1.98%)
Volume
AVERAGE VOLUME
5-Day
3,730
10-Day
2,919
30-Day
2,859
2,192
  • Prev. Close

    111.05

  • Open Price

    110.20

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    0.00 (0)

NSE Live

Feb 24, 15:59
113.35 2.60 (2.35%)
Volume
AVERAGE VOLUME
5-Day
16,152
10-Day
16,213
30-Day
19,339
36,256
  • Prev. Close

    110.75

  • Open Price

    108.00

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    113.35 (389)

ANNOUNCEMENTS ON Kilitch Drugs

  • Feb 15, 2020 19:13 Source: BSE

    Kilitch Drugs (India) - Announcement under Regulation 30 (LODR)-Newspaper Publication

    Pursuant to SEBI circular no.SEBI/HO/MIRSD/DOS3/CIR/P/2018/139 dated November 6, 2018, pleased find enclosed herewith Newspaper Advertisement relating to transfer of shares.

  • Feb 14, 2020 18:38 Source: BSE

    Kilitch Drugs (India) - Outcome Of Board Meeting Held On February 14, 2020

    Dear Sir/Madam, In continuation to our letter dated February 5, 2020, we wish to inform you that pursuant to Regulation 33 and Regulation 30 read with Para A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the company, at its meeting held today i.e. February 14, 2020, have 1.Considered & approved the standalone and consolidated Un-audited financial results of the company for the quarter ended December 31, 2019; 2.Approved the re-appointment of Mr. Hemang Engineer as an Independent Director for a second term of 5 years w.e.f. 1st April, 2020, subject to Member''s approval; 3.Approved the appointment of M/s. Deep Shukla & Associates, Company Secretaries to conduct Secretarial Audit of the Company for financial year ended 31st March, 2020; 4.Considered & approved the grant of additional 83869 options to the employees of the Company under ESOS Scheme.

  • Feb 05, 2020 15:38 Source: BSE

    Kilitch Drugs (India) - Board Meeting Intimation for To Consider And Approve The Standalone And Consolidated Un-Audited Financial Result Of The Company For The Quarter Ended December 31, 2019

    KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2020 ,inter alia, to consider and approve 1. To Consider and approve the Standalone and Consolidated Unaudited Financial Result of the Company for the quarter ended December 31st, 2019; 2. To consider the re-appointment of Mr. Hemang Engineer as an Independent Director of the Company; 3. To consider the appointment of M/s. Deep Shukla & Associates, Company Secretaries to conduct Secretarial Audit of the Company for financial year ended March 31st, 2020; 4. Any other matter with the permission of the chair.

  • Jan 16, 2020 15:38 Source: BSE

    Kilitch Drugs (India) - Shareholding for the Period Ended December 31, 2019

    Kilitch Drugs India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here

  • Jan 14, 2020 15:57 Source: NSE

    Kilitch Drugs (India) Limited

    Kilitch Drugs (India) Limited has informed the Exchange regarding 'Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018'.

  • Jan 14, 2020 15:11 Source: BSE

    Kilitch Drugs (India) - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

  • Jan 04, 2020 17:13 Source: BSE

    Kilitch Drugs (India) - Statement Of Investor Complaints For The Quarter Ended December 2019

    No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
    0110
    Name of the Signatory :- Harshal Patil
    Designation :- Company Secretary and Compliance Officer

  • Dec 31, 2019 16:27 Source: BSE

    Kilitch Drugs (India) - Closure of Trading Window

    With reference to the above subject, this is to inform you that pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time read with NSE Circular Reference no. NSE/CML/2019/11 and BSE Circular Reference no. LIST/COMP/01/2019-20, both dated April 02, 2019 Trading Window for dealing in Securities of the Company will remain closed for all Directors, Officers, Designated Persons of the Company and their immediate relatives with effect from Wednesday, January 1, 2020 till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter ended December 31, 2019.

  • Dec 17, 2019 14:57 Source: NSE

    Kilitch Drugs (India) Limited

    KILITCH:The Exchange has sought clarification from Kilitch Drugs (India) Limited with respect to announcement dated 09-Dec-2019, regarding " Kilitch Drugs (India) Limited has informed the Exchange regarding a press release dated December 09, 2019, titled "Kilitch Drugs to set-up second green field Project in Ethiopia at an investment of USD 5 mn".". On basis of above the Company is required to clarify following: 1. Existing capacity;

  • Dec 12, 2019 12:22 Source: NSE

    Kilitch Drugs (India) Limited

    Kilitch Drugs (India) Limited has informed the Exchange regarding Board meeting held on December 12, 2019.

CORPORATE ANNOUNCEMENTS

BOARD MEETING

Meeting Date : Feb 14, 2020
Remark : Quarterly Results & Others